 Eyenovia, Inc. EYEN a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, announced that today it closed its previously announced private placement of units which resulted in gross proceeds of 5,984,931 before deducting the placement agents fees and estimated offering expenses. Each unit consists of i one share of common stock, par value 0.0001 per share, ii a one-year warrant to purchase 0.5 of a share of common stock, and iii a five-year warrant to purchase 0.75 of a share of common stock. 